Gilead unveils results From two phase 3 studies evaluating tenofovir alafenamide for chronic HBV infection
Both studies met their primary endpoints of non-inferiority to Gilead’s Viread® (tenofovir disoproxil fumarate, TDF) 300 mg based on the percentage of patients with HBV DNA levels below
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.